NO20052960L - Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi - Google Patents

Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi

Info

Publication number
NO20052960L
NO20052960L NO20052960A NO20052960A NO20052960L NO 20052960 L NO20052960 L NO 20052960L NO 20052960 A NO20052960 A NO 20052960A NO 20052960 A NO20052960 A NO 20052960A NO 20052960 L NO20052960 L NO 20052960L
Authority
NO
Norway
Prior art keywords
lipodystrophy
treatment
docosahexaenoic acid
active substance
hiv
Prior art date
Application number
NO20052960A
Other languages
English (en)
Norwegian (no)
Inventor
Juan Carlos Domingo Pedrol
Pere Pedrol
Original Assignee
Proyecto Empresariel Brudy Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresariel Brudy Sl filed Critical Proyecto Empresariel Brudy Sl
Publication of NO20052960L publication Critical patent/NO20052960L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20052960A 2002-12-05 2005-06-16 Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi NO20052960L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200202963A ES2209658B1 (es) 2002-12-05 2002-12-05 Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
PCT/IB2003/005673 WO2004050077A1 (en) 2002-12-05 2003-12-01 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
NO20052960L true NO20052960L (no) 2005-06-16

Family

ID=32405973

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052960A NO20052960L (no) 2002-12-05 2005-06-16 Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi

Country Status (24)

Country Link
US (1) US8202906B2 (pl)
EP (1) EP1585513B1 (pl)
JP (1) JP2006511514A (pl)
KR (1) KR100906086B1 (pl)
CN (1) CN100355421C (pl)
AT (1) ATE326959T1 (pl)
AU (1) AU2003302679B2 (pl)
BR (1) BR0316973A (pl)
CA (1) CA2506993C (pl)
CY (1) CY1105205T1 (pl)
DE (1) DE60305534T2 (pl)
DK (1) DK1585513T3 (pl)
EA (1) EA009711B1 (pl)
ES (2) ES2209658B1 (pl)
IL (1) IL168766A (pl)
IS (1) IS2384B (pl)
MX (1) MXPA05005911A (pl)
NO (1) NO20052960L (pl)
NZ (1) NZ540262A (pl)
PL (1) PL377563A1 (pl)
PT (1) PT1585513E (pl)
UA (1) UA79650C2 (pl)
WO (1) WO2004050077A1 (pl)
ZA (1) ZA200503872B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5207342B2 (ja) * 2007-02-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN101990432B (zh) * 2008-01-03 2016-01-20 艾克斯-马赛大学 抗hiv治疗期间使用的组合物和方法
CN110339187B (zh) * 2019-07-30 2021-12-14 中国医学科学院病原生物学研究所 缓解寨卡病毒感染相关的新生儿小头症的药物
CN116585216A (zh) * 2022-05-16 2023-08-15 上海中翊日化有限公司 一种含有羟基频哪酮视黄酸酯(hpr)并降低光损伤及炎症的抗衰组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901048A1 (de) * 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
JPH0923817A (ja) * 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
FR2749133A1 (fr) 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CA2290885A1 (fr) * 1999-12-02 2001-06-02 Universite De Sherbrooke Methode pour la transformation des tissus du loup marin
EP1121928B1 (en) * 2000-01-31 2008-01-23 Härting S.A. Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides
JP2001314170A (ja) * 2000-05-09 2001-11-13 Toyo Shinyaku:Kk 麦若葉由来の素材を含む抗コレステロール食品
DE60022987T2 (de) * 2000-05-22 2006-10-19 Pro Aparts - Investimentos E Consultoria Lda., Funchal Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
BR0316973A (pt) 2005-10-25
CA2506993A1 (en) 2004-06-17
CN1720039A (zh) 2006-01-11
PT1585513E (pt) 2006-10-31
CN100355421C (zh) 2007-12-19
EP1585513B1 (en) 2006-05-24
AU2003302679A1 (en) 2004-06-23
ES2265607T3 (es) 2007-02-16
NZ540262A (en) 2006-11-30
EA009711B1 (ru) 2008-02-28
PL377563A1 (pl) 2006-02-06
IS2384B (is) 2008-07-15
JP2006511514A (ja) 2006-04-06
ZA200503872B (en) 2006-08-30
MXPA05005911A (es) 2005-08-29
UA79650C2 (en) 2007-07-10
DE60305534T2 (de) 2007-05-16
DK1585513T3 (da) 2006-09-18
EA200500765A1 (ru) 2005-12-29
KR20050085313A (ko) 2005-08-29
US8202906B2 (en) 2012-06-19
AU2003302679B2 (en) 2009-01-15
CA2506993C (en) 2010-04-13
EP1585513A1 (en) 2005-10-19
IL168766A (en) 2009-11-18
ATE326959T1 (de) 2006-06-15
US20060178436A1 (en) 2006-08-10
ES2209658A1 (es) 2004-06-16
DE60305534D1 (de) 2006-06-29
WO2004050077A1 (en) 2004-06-17
ES2209658B1 (es) 2005-10-01
IS7912A (is) 2005-06-23
CY1105205T1 (el) 2010-03-03
KR100906086B1 (ko) 2009-07-06

Similar Documents

Publication Publication Date Title
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
DE69930259D1 (de) Zusammensetzungen zur anwendung von entzündungshemmenden, insbesondere antiseptischen und/oder wundheilenden wirkstoffen im oberen atemwegtrakt und/oder ohr
ATE281839T1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
TW200637569A (en) Method of reducing oral tissue inflammation using magnolia extract
NO20004282L (no) Matriksproteinpreparater for sÕrheling
BRPI0313148B8 (pt) formulações sólidas matriciais de lamotrigina contendo revestimento externo e perfuração em tal revestimento
ATE332136T1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
ATE318610T1 (de) Orale zusammensetzungen zur behandlung von kopfhauterkrankungen
EP1192949A4 (en) PREVENTIVE OR THERAPEUTIC DRUGS FOR TREATING FIBROSIS AND CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS
ATE407690T1 (de) Topische pharmazeutische zusammensetzungen enthaltend aktive natürliche bestandteile zur verhütung und behandlung von mucosalen entzündungprozessen
NO20052960L (no) Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi
UY26474A1 (es) Inhibidores de aminotransferasa dependiente de aminoácidos de cadena ramificada, y su uso en el tratamiento de la retinopatía diabética.
DK1677806T3 (da) Sammensætninger til behandling af akut og overbelastningsforårsaget forstuvning og forstrækning ved anvendelse af hyaluronsyre
SE0950392L (sv) Sammansättning för behandling av hudåkommor
PT1414467E (pt) Tratamento topico da mastalgia
HUP0304077A2 (hu) A bőr öregedése elleni gyógyászati és kozmetikai készítmények
DE60305068D1 (de) Behandlung von mastalgie mit4-hydroxy-tamoxifen
BR0307211A (pt) Composições tópicas possuindo um ingrediente natural e método de utilização
DK1343472T3 (da) Thixotropisk næsespray
CO5261512A1 (es) Metodo y composiciones para el tratamiento de las enfermedades pulmonares
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE276658T1 (de) Wund- und schleimhautantiseptikum
NO20064196L (no) Utvortes preparat for behandling av smertefulle hudskader
RU2010144554A (ru) Средство для предотвращения и/или лечения сосудистых заболеваний

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application